SynthesisScientific reports2017
An overall and dose-response meta-analysis of red blood cell distribution width and CVD outcomes.
Synthesis in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04238338 (Association of Monocyte / Lymphocyte Ratio With Risk of Death and Cardiovascular Events in Peritoneal Dialysis Patients), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Association of Monocyte / Lymphocyte Ratio With Risk of Death and Cardiovascular Events in Peritoneal Dialysis Patients
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and dose-response meta-analysis of red blood cell distribution width to albumin ratio as mortality predictor in cardiovascular disease.Scientific reports · 2025Pooled it
- The incremental prognostic effect of red blood cell distribution width in 28-day mortality among critically ill patients with HFpEF.American heart journal plus : cardiology research and practice · 2026Article
- [Elevation of red blood cell distribution width to hematocrit ratio is associated with increased 28-day all-cause mortality in septic patients].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- A single postoperative red cell distribution width measurement predicts short- and long-term mortality in surgical patients.Wiener medizinische Wochenschrift (1946) · 2026Article
- High red cell distribution width as a prognostic indicator in heart failure.World journal of methodology · 2026Article
- The role of red blood cell distribution width in prognosis prediction among critically ill patients with obstructive sleep apnea: Insights from the MIMIC-IV database.Scientific reports · 2026Article
- Prognostic utility of red blood cell distribution width-based ratios and their individual components for mortality prediction in dogs with acute pancreatitis.Frontiers in veterinary science · 2026Article
- Development and external validation of an interpretable machine learning model for diagnosing coronary heart disease in patients with type 2 diabetes and MASLD.Frontiers in endocrinology · 2026Article
- Prognostic Impact of the Ratio of Hemoglobin to Red Blood Cell Distribution Width in Patients after Acute Decompensated Heart Failure.Internal medicine (Tokyo, Japan) · 2025Article
- Association between red blood cell distribution width coefficient of variation and post-treatment bilirubin decline velocity in neonatal hyperbilirubinemia.Frontiers in pediatrics · 2025Article
- The Prognostic Role of RDW in Hospitalized Heart Failure Patients with and Without Chronic Kidney Disease.Journal of clinical medicine · 2024Article
- Blood Biomarkers Predict 10-Year Clinical Outcomes in Adult Patients With Congenital Heart Disease.JACC. Advances · 2024Article
- Novel Systemic Inflammatory Markers Predict All-Cause Mortality in Patients Undergoing Endovascular Abdominal Aortic Aneurysm Repair.Reviews in cardiovascular medicine · 2024Article
- Association between elevated preoperative red cell distribution width and mortality after brain tumor craniotomy.Neurosurgical review · 2024Article
- Exposure to Fine Particulate Matter Air Pollution Disrupts Erythrocyte Turnover.Circulation research · 2024Article
- Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan.ESC heart failure · 2024Article
- Relationship Between the Hemoglobin-to-Red Cell Distribution Width Ratio and in-Hospital Mortality in Patients with Chronic Heart Failure.Vascular health and risk management · 2024Article
- Predictive Value of the Hb/RDW Ratio for the Risk of All-Cause Death in Patients with Heart Failure with Different Ejection Fractions.Cardiology · 2024Article
- Development and Validation of a Predictive Model Based on LASSO Regression: Predicting the Risk of Early Recurrence of Atrial Fibrillation after Radiofrequency Catheter Ablation.Diagnostics (Basel, Switzerland) · 2023Article
- The relationship between hemoglobin/red blood cell distribution width ratio and mortality in patients with intracranial hemorrhage: a possible protective effect for the elderly?Internal and emergency medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Red blood cell distribution width (RDW) is the coefficient of variation of red blood cell size, considered to be associated with cardiovascular disease (CVD). This study aimed to comprehensively synthesize previous studies on RDW and CVD outcomes through an overall and dose-response meta-analysis. PubMed, Embase and Web of Science were searched systematically for English and Chinese language publications up to November 30, 2015. We extracted data from publications matching our inclusion criteria for calculating pooled hazard ratio (HR), which was used to assess prognostic impact of RDW on CVD. Twenty-seven articles, consisting of 28 studies and 102,689 participants (mean age 63.9 years, 63,703 males/36,846 females, 2,140 gender-unmentioned subjects) were included in the present meta-analysis. The pooled HRs are 1.12 (95% CI = 1.09-1.15) for the association of all-cause mortality (ACM) per 1% increase of RDW, 1.12(95% CI = 1.08-1.17) for major adverse cardiac events (MACEs) per 1% increase of RDW. A dose-response curve relating RDW increase to its effect on CVD outcomes was established (p
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.